- Home
- SMBC vs BBOT Comparison
SMBC vs BBOT Comparison
Compare SMBC & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SMBC | BBOT |
|---|---|---|
| Founded | 1887 | 2016 |
| Country | United States | United States |
| Employees | N/A | 106 |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 762.1M | 705.7M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | SMBC | BBOT |
|---|---|---|
| Price | $70.27 | $7.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $69.50 | $24.00 |
| AVG Volume (30 Days) | 61.4K | ★ 344.8K |
| Earning Date | 04-22-2026 | 05-26-2026 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.59 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.09 | N/A |
| Revenue Next Year | $5.69 | N/A |
| P/E Ratio | $15.03 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $47.60 | $7.60 |
| 52 Week High | $70.35 | $14.87 |
Technical Indicators
Market Signals| Indicator | SMBC | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 59.45 | 40.34 |
| Support Level | $63.78 | N/A |
| Resistance Level | N/A | $9.50 |
| Average True Range (ATR) | 1.55 | 0.54 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 94.03 | 10.18 |
Price Performance
Historical ComparisonAbout SMBC Southern Missouri Bancorp Inc.
Southern Missouri Bancorp Inc is a USA-based holding company for Southern Missouri Savings Bank. The principal business of the bank consists of attracting retail deposits from the general public and using such deposits along with wholesale funding from the Federal Home Loan Bank of Des Moines, and to a lesser extent, brokered deposits, to invest in one- to four-family residential mortgage loans, mortgage loans secured by commercial real estate, commercial non-mortgage business loans, and consumer loans. It is engaged in providing the range of banking and financial services to individuals and corporate customers in its market areas. The company derives revenue principally from interest earned on loans, debt securities, bank card interchange fees, loan late charges and another fee income.
About BBOT BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.